Background pattern
PRALUENT 150 mg SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE

PRALUENT 150 mg SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use PRALUENT 150 mg SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE

Introduction

Package Leaflet: Information for the User

Praluent 75mg solution for injection in pre-filled syringe

Praluent 150 mg solution for injection in pre-filled syringe

alirocumab

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Praluent and what is it used for
  2. What you need to know before you use Praluent
  3. How to use Praluent
  4. Possible side effects
  5. Storage of Praluent
  6. Contents of the pack and other information

1. What is Praluent and what is it used for

What is Praluent

  • The active substance of Praluent is alirocumab.
  • Praluent is a monoclonal antibody (a type of specialized protein designed to bind to a target substance in the body). Monoclonal antibodies are proteins that recognize and bind to other unique proteins. Alirocumab binds to PCSK9.

How Praluent works

Praluent helps to reduce your levels of "bad" cholesterol (also called "LDL cholesterol"). Praluent blocks a protein called PCSK9.

  • PCSK9 is a protein secreted by liver cells.
  • Normally, "bad" cholesterol is removed from the blood by binding to specific "receptors" (docking stations) in the liver.
  • PCSK9 reduces the number of these receptors in the liver, which causes "bad" cholesterol levels to be higher than they should be.
  • By blocking PCSK9, Praluent increases the number of available receptors to help remove "bad" cholesterol and thus reduces "bad" cholesterol levels.

What Praluent is used for

  • In adults with high cholesterol levels in their blood (heterozygous and non-familial hypercholesterolemia or mixed dyslipidemia) and children and adolescents aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
  • To reduce the risk of cardiovascular events in adults with high cholesterol levels in the blood and with established cardiovascular disease.

It is given:

  • in combination with a statin (a medicine commonly used to treat high cholesterol) or with other medicines to lower cholesterol, if the maximum dose of a statin does not sufficiently lower cholesterol levels, or
  • alone or with another cholesterol-lowering medicine when statins are not tolerated or cannot be used.
  • Continue with your cholesterol-lowering diet while taking this medicine.

2. What you need to know before you use Praluent

Do not use Praluent

  • if you are allergic to alirocumab or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor, pharmacist, or nurse before starting treatment with Praluent.

If you experience a severe allergic reaction, stop treatment with Praluent and go to your doctor immediately. Sometimes, severe allergic reactions have occurred, such as hypersensitivity, including angioedema (difficulty breathing, or swelling of the face, lips, throat, or tongue), nummular eczema (red patches on the skin, sometimes with blisters), and hypersensitivity vasculitis (a specific type of hypersensitivity reaction with symptoms such as diarrhea, with a skin rash, or purple-colored spots on the skin). For a list of allergic reactions that may occur while taking Praluent, see section 4.

Tell your doctor before using this medicine if you have any kidney or liver disease, as Praluent has been studied in few patients with severe kidney disease and in no patients with severe liver disease.

Children and adolescents

Praluent must not be given to children under 8 years of age because there is no experience with the use of this medicine in this age group.

Using Praluent with other medicines

Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use any other medicines.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Praluent is not recommended during pregnancy or breastfeeding.

Driving and using machines

This medicine is not expected to affect your ability to drive or use machines.

3. How to use Praluent

Follow exactly the administration instructions for this medicine given by your doctor, pharmacist, or nurse. If you are unsure, consult your doctor, pharmacist, or nurse again. The outer packaging also contains instructions for use.

How much to inject

Your doctor will tell you what dose is right for you and how often you should inject it (75 mg or 150 mg every 2 weeks or 300 mg every 4 weeks/monthly). Your doctor will check your cholesterol levels and may adjust the dose (increase or decrease) during treatment.

Always check the name and concentration of the medicine on the syringe label.

When to inject

Inject Praluent every 2 weeks (for 75 mg or 150 mg doses) or every 4 weeks/monthly (for 300 mg dose). To administer the 300 mg dose, give two consecutive 150 mg injections in two different injection sites.

The pre-filled syringes are not intended for use in children and adolescents aged 8 years and older.

Before injecting

Praluent should be allowed to reach room temperature before use.

Read the detailed instructions for use in the package leaflet before injecting Praluent.

Where to inject

Praluent is injected under your skin in the thigh, abdomen, or upper arm.

Read the detailed instructions for use in the package leaflet on where to inject.

How to use the pre-filled syringe

Before using the syringe for the first time, your doctor, pharmacist, or nurse will show you how to inject Praluent.

  • Always read the "Instructions for use"that come with the carton.
  • Always use the syringe as described in the "Instructions for use".

If you use more Praluent than you should

If you use more Praluent than you should, talk to your doctor, pharmacist, or nurse.

If you forget to use Praluent

If you miss a dose of Praluent, inject the missed dose as soon as possible. Then, inject the next dose at the usual scheduled time. This will keep you on your original schedule. If you are unsure when to inject Praluent, consult your doctor, pharmacist, or nurse.

If you stop using Praluent

Do not stop treatment with Praluent without first talking to your doctor. If you stop treatment with Praluent, your cholesterol levels may increase.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you experience a severe allergic reaction, stop treatment with Praluent and go to your doctor immediately. Sometimes, severe allergic reactions have occurred, such as hypersensitivity (difficulty breathing), nummular eczema (red patches on the skin, sometimes with blisters), and hypersensitivity vasculitis (a specific type of hypersensitivity reaction with symptoms such as diarrhea, with a skin rash, or purple-colored spots on the skin) (may affect up to 1 in 1,000 people).

Other side effects are:

Common(may affect up to 1 in 10 people)

  • redness, itching, swelling, pain/tenderness at the injection site (local reactions at the injection site)
  • signs or symptoms of upper respiratory tract infection such as sore throat, nasal secretion, sneezing
  • itching (pruritus).

Rare(may affect up to 1 in 1,000 people)

  • red, itchy, raised patches on the skin (urticaria).

Frequency not known

Since the marketing authorization of Praluent, the following side effects have been reported, with a frequency not known:

  • flu-like illness.
  • difficulty breathing, or swelling of the face, lips, throat, or tongue (angioedema).

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Praluent

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date is the last day of the month shown.

Store in a refrigerator (2°C - 8°C). Do not freeze.

Keep the pre-filled syringe in the outer carton to protect it from light.

If necessary, individual pre-filled syringes may be stored at room temperature (below 25°C) for a maximum of 30 days. Protected from light. After removal from the refrigerator, Praluent must be used within 30 days or discarded.

Do not use this medicine if it has changed color, is cloudy, or contains visible particles.

After use, put the syringe in a puncture-resistant container. Ask your doctor, pharmacist, or nurse how to dispose of the container. Do not recycle the container.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Container Contents and Additional Information

Praluent Composition

  • The active ingredient is alirocumab.

Praluent 75 mg injectable solution in pre-filled syringe

Each single-use syringe contains 75 milligrams of alirocumab.

Praluent 75 mg injectable solution in pre-filled syringe

Each single-use syringe contains 150 milligrams of alirocumab.

  • The other components are histidine, sucrose, polysorbate 20, and water for injectable preparations.

Product Appearance and Container Contents

Praluent is a clear, colorless to pale yellow injectable solution presented in a pre-filled syringe.

Praluent 75 mg injectable solution in pre-filled syringe

Each pre-filled syringe with a green plunger contains 1 ml of solution that delivers a single dose of 75 milligrams of alirocumab.

It is available in packs of 1, 2, or 6 pre-filled syringes.

Praluent 150 mg injectable solution in pre-filled syringeEach pre-filled syringe with a gray plunger contains 1 ml of solution that delivers a single dose of 150 milligrams of alirocumab.

It is available in packs of 1, 2, or 6 pre-filled syringes.

Not all pack sizes and presentations may be marketed.

Marketing Authorization Holder

Sanofi Winthrop Industrie

82 avenue Raspail

94250 Gentilly France

Manufacturer

Sanofi Winthrop Industrie

1051 Boulevard Industriel

76580 Le Trait

France

You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:

Belgium

Sanofi Belgium

Tel: +32 (0)2 710 54 00

Lithuania

Swixx Biopharma UAB

Tel: +370 5 236 91 40

Text with the name of the company Swixx Biopharma EODD and its phone number +359 (0)2 4942 480

Luxembourg

Sanofi Belgium

Tel: +32 (0)2 710 54 00 (Belgium)

Czech Republic

Sanofi s.r.o.

Tel: +420 233 086 111

Hungary

SANOFI-AVENTIS Zrt., Hungary

Tel.: +36 1 505 0050

Denmark

Sanofi A/S

Tlf: +45 45 16 70 00

Malta

Sanofi S.r.l.

Tel: +39 02 39394275

Germany

Sanofi-Aventis Deutschland GmbH

Tel.: 0800 52 52 010

Tel. from abroad: +49 69 305 21 131

Netherlands

Sanofi B.V.

Tel: +31 20 245 4000

Estonia

Swixx Biopharma OÜ

Tel: +372 640 10 30

Norway

sanofi-aventis Norge AS

Tlf: +47 67 10 71 00

Greece

Sanofi-Aventis Μονοπρ?σωπη AEBE

Τηλ: +30 210 900 16 00

Austria

sanofi-aventis GmbH

Tel: +43 1 80 185 – 0

Spain

sanofi-aventis, S.A

Tel: +34 93 485 94 00

Poland

Sanofi Sp. z o.o.

Tel.: +48 22 280 00 00

France

Sanofi Winthrop Industrie

Tél: 0 800 222 555

Appel depuis l’étranger : +33 1 57 63 23 23

Portugal

Sanofi - Produtos Farmacêuticos, Lda.

Tel: +351 21 35 89 400

Croatia

Swixx Biopharma d.o.o.

Tel: +385 1 2078 500

Romania

Sanofi Romania SRL

Tel: +40 (0) 21 317 31 36

Ireland

sanofi-aventis Ireland Ltd. T/A SANOFI

Tel: +353 (0) 1 403 56 00

Slovenia

Swixx Biopharma d.o.o.

Tel: +386 1 235 51 00

Iceland

Vistor hf.

Sími: +354 535 7000

Slovak Republic

Swixx Biopharma s.r.o.

Tel: +421 2 208 33 600

Italy

Sanofi S.r.l.

Tel: 800 131212 (technical inquiries)

800 536389 (other inquiries)

Finland

Sanofi Oy

Puh/Tel: +358 (0) 201 200 300

Cyprus

C.A. Papaellinas Ltd.

Τηλ: +357 22 741741

Sweden

Sanofi AB

Tel: +46 (0)8 634 50 00

Latvia

Swixx Biopharma SIA

Tel: +371 6 616 47 50

United Kingdom (Northern Ireland)

sanofi-aventis Ireland Ltd. T/A SANOFI

Tel: +44 (0) 800 035 2525

Date of Last Revision of this Leaflet:

Detailed information on this medicinal product is available on the European Medicines Agency web site: http://www.ema.europa.eu.

Praluent Pre-filled Syringe

Instructions for Use

The following image shows the parts of the Praluent syringe.

Pre-filled transparent syringe with gray liquid and labels “Praluent” and “150 mg” showing body, plunger, and needle cap with detail of the needle

Important Information

  • The medicine is injected under the skin and can be administered by you or another person (caregiver).
  • This syringe is for single use only and should be discarded after use.

What to Do

  • Keep the Praluent syringe out of sight and reach of children.
  • Read all instructions carefully before using the Praluent syringe.
  • Follow these instructions each time you use a Praluent syringe.

What Not to Do

  • Do not touch the needle.
  • Do not use the syringe if it has been dropped or is damaged.
  • Do not use the syringe if the gray needle cap is missing or not firmly attached.
  • Do not reuse the syringe.
  • Do not shake the syringe.
  • Do not freeze the syringe.
  • Do not expose the syringe to direct sunlight.

Keep this leaflet. If you have any further questions, ask your doctor, pharmacist, or nurse, or call the sanofi-aventis number listed in the leaflet.

STEP A: Preparing the Injection

Before You Start, You Will Need:

  • The Praluent syringe
  • Alcohol wipes
  • A cotton ball or gauze
  • A sharps container (see Step B, 6).

?Before You Start.

  • Remove the syringe from the packaging by holding the body.

Hand holding a pre-filled transparent syringe with blue and gray liquid, ready for injection

?Look at the Syringe Label.

  • Check that it contains the correct medicine and dose (gray plunger for 150 mg/ml).
  • Check the expiration date on the syringe and do not use it if it is expired.
  • Check that the liquid is clear, colorless to pale yellow, and does not contain particles; otherwise, do not use the syringe.
  • Check that the syringe is not open or damaged.

?Allow the Syringe to Reach Room Temperature (30 to 40 minutes).

  • Let the syringe come to room temperature on its own; do not try to warm it up.
  • Do not put the syringe back in the refrigerator.

?Prepare the Injection Site.

  • Wash your hands with soap and water and dry them with a towel.
  • You can inject into:
  • the thigh
  • the abdomen (except for the area within 5 cm around the navel)
  • the upper outer arm

(See image).

  • You can inject while standing or sitting.
  • Clean the skin at the injection site with an alcohol wipe.
  • Do not choose an area of skin that is painful, hardened, red, or inflamed.
  • Do not choose an area close to a visible vein.
  • Inject each time in a different area.
  • Do not inject Praluent together with other injectable medicines in the same area.

Diagram of the human torso with orange areas indicating injection sites on the abdomen, thighs, and arms

STEP B: How to Inject

?After Completing All Steps in “Step A: Preparing the Injection”, Remove the Needle Cap.

  • Do not remove the cap until you are ready to inject.
  • Hold the middle part of the syringe with the needle facing away from you.
  • Do not touch the plunger.
  • A small air bubble may be present. This is normal. Do not try to remove any air bubble that may be present in the syringe before injection.
  • Do not replace the gray cap.

Hand holding syringe with exposed needle and visible plunger, arrow indicating direction of needle cap

?If Necessary, Pinch the Skin.

  • Pick up a fold of skin at the injection site between your thumb and index finger.
  • Do not release the skin fold during the entire injection.

Hand pinching the skin with thumb and index finger preparing for a subcutaneous injection in the abdomen

?Insert the Needle into the Skin Fold with a Quick Darting Motion.

  • If you can pinch 5 cm of skin, use a 90-degree angle.
  • If you can only pinch 2 cm of skin, use a 45-degree angle.

Hand holding syringe with 90-degree angle and inserting needle into skin, and another hand with 45-degree angle showing injection technique

?Push the Plunger.

  • Inject all of the solution by slowly and steadily pushing the plunger.

Hand holding pre-filled syringe with transparent liquid inserting needle into skin of another hand with an orange arrow indicating direction

?Before Withdrawing the Needle, Check that the Syringe is Empty.

  • Do not withdraw the syringe until it is completely empty.
  • Remove the needle from the skin at the same angle as it was inserted.
  • Do not rub the injection site after the injection.
  • If bleeding occurs, press the injection site with a cotton ball or gauze until the bleeding stops.

Hand holding auto-injector with an orange arrow indicating pressure on the skin of the abdomen

?Dispose of the Syringe and Needle Cap.

  • Do not replace the gray needle cap.
  • Do not reuse the syringe.
  • Dispose of the syringe and needle cap in a sharps container immediately after use.
  • Ask your doctor, pharmacist, or nurse how to dispose of the container.
  • Always keep the container out of sight and reach of children.

Hand holding auto-injector over a vial with an orange arrow indicating direction of insertion and a separate vial cap

Get updates and exclusive offers

Be the first to know about new services, marketplace updates, and subscriber-only promos.

Follow us on social media
FacebookInstagram
Logo
Oladoctor
Find a doctor
Doctors by specialty
Services
Choose language
© 2025 Oladoctor. All rights reserved.
VisaMastercardStripe